Anti‑vascular endothelial growth factor (anti‑VEGF) agents including Bevacizumab,
Ranibizumab, Aflibercept, and the latest molecule Brolucizumab have caused a paradigm …

Purpose: The aim of this study was to present the outcomes of the 2018 and 2020 Vitreo-
retinal Society of India (VRSI) biosimilars of anti-vascular endothelial growth factor …

Purpose To review the biosimilars of anti–vascular endothelial growth factor agents for
retinal diseases and provide an update about their development. Design Literature review …

Retina as a subspecialty has transformed since the introduction of anti-vascular endothelial
growth factor (anti-VEGF) therapeutics more than a decade ago. Approved intravitreal anti …

Retinal disease management has witnessed remarkable advances in posterior segment
pharmacotherapy with the development of anti-VEGF molecules such as Lucentis® …

Overview Biosimilars have been spreading widely in the field of ophthalmology since the
patent expiry of innovator molecules. The patent of the ranibizumab innovator has already …

The advent of intravitreal vascular endothelial growth factor (anti‑VEGF) therapy has
radically improved the anatomical and visual outcomes of neovascular age‑related macular …

Antivascular endothelial growth factor (anti-VEGF) therapy has revolutionized the
management of retinal vascular diseases. However, the cost of this therapy resulting from …

Sir, India has been on the forefront of biosimilar development for ophthalmic therapeutics by
developing and commercially marketing Razumab®(Intas Pharmaceuticals, Ahmedabad …

There has been a growing interest in the biosimilars of antivascular endothelial growth factor
(VEGF). 1 There are various biosimilar molecules of ranibizumab and aflibercept at various …